Kura Oncology, Inc.
Congressional Trades
| Politician | Stock | Type | Filed | Traded | |
|---|---|---|---|---|---|
Christopher L. JacobsHouse · R · NY |
KURAKura Oncology, Inc. · Stock |
Purchase $1,001 - $15,000 |
Jan 20, 2023 | Dec 12, 2022 | Filing ↗ |
Whale Activity
- Increased83
- New35
- Held31
- Decreased71
- Closed23
- No prior filing11
| Filer | Shares | Value | Change |
|---|---|---|---|
| BlackRock, Inc. | 11.8M | $125.9M | increased |
| MONTANOVA CAPITAL, LLC | 7.9M | $84.6M | decreased |
| BVF INC/IL | 6.7M | $71.7M | decreased |
| STATE STREET CORP | 4.7M | $50.4M | decreased |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.9M | $41.8M | decreased |
| AQR CAPITAL MANAGEMENT LLC | 3.7M | $39.5M | increased |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 2.8M | $29.5M | increased |
| GEODE CAPITAL MANAGEMENT, LLC | 2.3M | $24.6M | increased |
| ALETHEA CAPITAL MANAGEMENT, LLC | 2.2M | $23.3M | increased |
| ARMISTICE CAPITAL, LLC | 2.1M | $22.4M | decreased |
| RENAISSANCE TECHNOLOGIES LLC | 2.0M | $21.5M | increased |
| GOLDMAN SACHS GROUP INC | 2.0M | $21.2M | decreased |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
Recent Insider Transactions
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Powl Brian T.Chief Commercial Officer | Sale | −448 | $7.27 | $3K | Nov 19, 2026 | Form 4 ↗ |
| Leoni MollieChief Medical Officer | Sale | −22.2K | $7.45 | $166K | Nov 17, 2026 | Form 4 ↗ |
| Powl Brian T.Chief Commercial Officer | Sale | −15.3K | $7.45 | $114K | Nov 17, 2026 | Form 4 ↗ |
| FORD KATHLEENChief Operating Officer | Sale | −3,668 | $7.46 | $27K | Nov 17, 2026 | Form 4 ↗ |
| DOYLE THOMAS JAMESSVP, Finance & Accounting | Sale | −4,697 | $7.44 | $35K | Nov 16, 2026 | Form 4 ↗ |
| Leoni MollieChief Medical Officer | Sale | −19.0K | $7.44 | $141K | Nov 16, 2026 | Form 4 ↗ |
| Powl Brian T.Chief Commercial Officer | Sale | −9,196 | $7.44 | $68K | Nov 16, 2026 | Form 4 ↗ |
| Bair Teresa BrophyChief Legal Officer | Sale | −8,601 | $7.44 | $64K | Nov 16, 2026 | Form 4 ↗ |
| FORD KATHLEENChief Operating Officer | Sale | −7,042 | $7.44 | $52K | Nov 16, 2026 | Form 4 ↗ |
| WILSON TROY EDWARDPresident and CEO · Director | Purchase Amended | +101.1K | $7.42 | $750K | Nov 16, 2026 | Form 4 ↗ |
| WILSON TROY EDWARDPresident and CEO · Director | Purchase | +101.1K | $7.42 | $750K | Nov 16, 2026 | Form 4 ↗ |
| WILSON TROY EDWARDPresident and CEO · Director | Purchase Amended | +98.9K | $7.63 | $754K | Nov 13, 2026 | Form 4 ↗ |
| WILSON TROY EDWARDPresident and CEO · Director | Purchase | +98.9K | $7.63 | $754K | Nov 13, 2026 | Form 4 ↗ |
| FORD KATHLEENChief Operating Officer | Sale | −3,668 | $10.75 | $39K | Sep 29, 2026 | Form 4 ↗ |
| Leoni MollieChief Medical Officer | Sale | −28.8K | $10.75 | $310K | Sep 29, 2026 | Form 4 ↗ |
| Powl Brian T.Chief Commercial Officer | Sale | −15.4K | $10.75 | $166K | Sep 29, 2026 | Form 4 ↗ |
| Bair Teresa BrophyChief Legal Officer | Sale | −8,442 | $10.50 | $89K | Sep 28, 2026 | Form 4 ↗ |
| FORD KATHLEENChief Operating Officer | Sale | −6,906 | $10.50 | $73K | Sep 28, 2026 | Form 4 ↗ |
| Leoni MollieChief Medical Officer | Sale | −12.4K | $10.50 | $131K | Sep 28, 2026 | Form 4 ↗ |
| DOYLE THOMAS JAMESSVP, Finance & Accounting | Sale | −4,607 | $10.50 | $48K | Sep 28, 2026 | Form 4 ↗ |
Fund Holders
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST | 3.1M | $34.1M | 0.32% | Jun 30, 2026 |
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 2.8M | $30.7M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF iShares Trust | 2.2M | $24.3M | 0.03% | Jun 30, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 1.0M | $11.3M | 0.01% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF iShares Trust | 785.1K | $8.6M | 0.06% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund Fidelity Salem Street Trust | 929.0K | $8.4M | 0.02% | Jul 31, 2026 |
| BlackRock Advantage Small Cap Core Fund BlackRock Funds | 526.6K | $6.7M | 0.12% | Aug 31, 2026 |
| iShares Biotechnology ETF iShares Trust | 606.1K | $6.6M | 0.07% | Jun 30, 2026 |
| VANGUARD RUSSELL 2000 INDEX FUND VANGUARD SCOTTSDALE FUNDS | 488.0K | $6.2M | 0.03% | Aug 31, 2026 |
| Fidelity Extended Market Index Fund Fidelity Concord Street Trust | 442.4K | $5.6M | 0.01% | Aug 31, 2026 |
Mutual funds and ETFs whose N-PORT filings list KURA's shares (CUSIP 50127T109), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
- BVF INC/ILSCHEDULE 13G/A · passive (13G) · 6.7M shares7.5%
Nov 16, 2026 · ↗ - BVF PARTNERS L P/ILSCHEDULE 13G/A · passive (13G) · 6.7M shares7.5%
Nov 16, 2026 · ↗ - BVF GP HOLDINGS LLCSCHEDULE 13G/A · passive (13G) · 6.1M shares6.9%
Nov 16, 2026 · ↗ - BVF Partners OS Ltd.SCHEDULE 13G/A · passive (13G) · 443.4K shares0.5%
Nov 16, 2026 · ↗ - Biotechnology Value Trading Fund OS LPSCHEDULE 13G/A · passive (13G) · 443.4K shares0.5%
Nov 16, 2026 · ↗ - BVF II GP LLCSCHEDULE 13G/A · passive (13G) · 2.6M shares2.9%
Nov 16, 2026 · ↗ - BIOTECHNOLOGY VALUE FUND II LPSCHEDULE 13G/A · passive (13G) · 2.6M shares2.9%
Nov 16, 2026 · ↗ - BVF I GP LLCSCHEDULE 13G/A · passive (13G) · 3.5M shares3.9%
Nov 16, 2026 · ↗ - LAMPERT MARK NSCHEDULE 13G/A · passive (13G) · 6.7M shares7.5%
Nov 16, 2026 · ↗ - BIOTECHNOLOGY VALUE FUND L PSCHEDULE 13G/A · passive (13G) · 3.5M shares3.9%
Nov 16, 2026 · ↗
Corporate Lobbying
No lobbying filings found naming Kura Oncology, Inc. as the client.
Government Contracts
No federal contract awards found for Kura Oncology, Inc..
U.S. Patents
No USPTO patent applications found for Kura Oncology, Inc..
Annual Financials
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $67.5M | $53.9M | $0 | n/a | n/a |
| Operating income | -$303.6M | -$193.2M | -$165.8M | -$139.9M | n/a |
| Net income | -$278.7M | -$174.0M | -$152.6M | -$135.8M | -$130.5M |
| Diluted EPS | -$3.18 | -$2.02 | -$2.08 | -$2.03 | -$1.97 |
| Operating cash flow | -$64.1M | $134.3M | -$124.8M | -$110.1M | -$104.6M |
| Cash and equivalents | $149.1M | $224.5M | $37.3M | $51.8M | $90.7M |
| Total assets | $738.4M | $760.2M | $448.9M | $456.3M | $534.1M |
| Total liabilities | $564.2M | $346.5M | $51.7M | $36.0M | $27.4M |
| Shareholders' equity | $174.1M | $413.6M | $397.3M | $420.3M | $506.6M |
As Kura Oncology, Inc. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Mar 5, 2026 ↗
Stock Splits
No stock splits in KURA's price history.
Material Events (8-K)
- 8-K · Items 2.02, 9.01Results of operationsNov 10, 2026
EDGAR ↗ - 8-K · Items 8.01Other eventsSep 9, 2026
EDGAR ↗ - 8-K · Items 5.02Officer / director changeSep 8, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsAug 12, 2026
EDGAR ↗ - 8-K · Items 5.02Officer / director changeJul 29, 2026
EDGAR ↗ - 8-K · Items 5.02, 5.07, 9.01Officer / director change · Shareholder voteJun 4, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsMay 12, 2026
EDGAR ↗

